

# Chronic hand eczema - Pipeline Insight, 2021

<https://marketpublishers.com/r/CCFE8A0D4DFBEN.html>

Date: May 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: CCFE8A0D4DFBEN

## Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Chronic hand eczema - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chronic hand eczema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Chronic hand eczema Understanding

#### Chronic hand eczema: Overview

Chronic hand eczema (CHE) is a common inflammatory skin condition. In Chronic hand eczema, affected areas of skin feel hot, painful, rough, scaly and itchy. There may be itchy little blisters or painful cracks. This may in turn, result in pain when moving the hand and fingers. CHE is a common dermatological condition with frequent relapses, occurs possibly as a result of long-term exposure to various irritants and allergens. There is a large unmet need for effective therapeutics for long-term control of CHE, particularly moderate-to-severe cases. Management of hand eczema is complex because of the broad range of different pathogeneses, courses, and prognoses. Patient education, preventive measures, and the use of emollients are the mainstays in the management of hand eczema. High-potency topical corticosteroids are the treatment of

choice, with calcineurin inhibitors used for maintenance.

'Chronic hand eczema - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic hand eczema pipeline landscape is provided which includes the disease overview and Chronic hand eczema treatment guidelines. The assessment part of the report embraces, in depth Chronic hand eczema commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic hand eczema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

### Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic hand eczema R&D. The therapies under development are focused on novel approaches to treat/improve Chronic hand eczema.

In February 2021, The Food and Drug Administration (FDA) has granted Fast Track designation to gusacitinib (ASN002) for the treatment of moderate to severe chronic hand eczema.

### Chronic hand eczema Emerging Drugs Chapters

This segment of the Chronic hand eczema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### Chronic hand eczema Emerging Drugs

**Delgocitinib: LEO Pharma**

Delgocitinib (LP0133) is a topical pan-Janus kinase (JAK) inhibitor that blocks the

activation of the JAK-STAT pathway, which has been shown to play a key role in the pathophysiology of chronic inflammatory skin diseases. The Food and Drug Administration (FDA) has granted Fast Track designation to delgocitinib cream for the treatment of adults with moderate to severe chronic hand eczema. The drug is in Phase II clinical evaluation for the treatment of adults with mild to severe chronic hand eczema. In 2014, LEO Pharma A/S and Japan Tobacco Inc. (JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan, where JT retains rights.

#### ASN002: Asana BioSciences

ASN002 (Gusacitinib) is a potent dual inhibitor of JAK and SYK kinases, which are involved in both cytokine production and signaling. ASN002 inhibits JAK-mediated cytokine signaling and JAK-SYK mediated T- and B-cell proliferation and function. Gusacitinib completed Phase 2 clinical evaluation in moderate-to-severe chronic hand eczema (CHE) patients.

Further product details are provided in the report

#### Chronic hand eczema: Therapeutic Assessment

This segment of the report provides insights about the different Chronic hand eczema drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Chronic hand eczema

There are approx. 5+ key companies which are developing the therapies for Chronic hand eczema. The companies which have their Chronic hand eczema drug candidates in the most advanced stage, i.e. Phase II include, LEO Pharma.

#### Phases

DelveInsight's report covers around 45+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Chronic hand eczema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic hand eczema: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chronic hand eczema therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic hand eczema drugs.

Chronic hand eczema Report Insights

Chronic hand eczema Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Chronic hand eczema Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Chronic hand eczema drugs?

How many Chronic hand eczema drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic hand eczema?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic hand eczema therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Chronic hand eczema and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

LEO Pharma

Arcutis Biotherapeutics

Asana BioSciences

## Key Products

Delgocitinib

ARQ 252

ASN002

## Contents

- Introduction
- Executive Summary
- Chronic hand eczema: Overview
  - Causes
  - Mechanism of Action
  - Signs and Symptoms
  - Diagnosis
  - Disease Management
- Pipeline Therapeutics
  - Comparative Analysis
- Therapeutic Assessment
  - Assessment by Product Type
  - Assessment by Stage and Product Type
  - Assessment by Route of Administration
  - Assessment by Stage and Route of Administration
  - Assessment by Molecule Type
  - Assessment by Stage and Molecule Type
- Chronic hand eczema – DelveInsight's Analytical Perspective
- In-depth Commercial Assessment
  - Chronic hand eczema companies' collaborations, Licensing, Acquisition -Deal Value
- Trends
- Chronic hand eczema Collaboration Deals
  - Company-Company Collaborations (Licensing / Partnering) Analysis
  - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
  - Comparative Analysis
- Drug name: Company name
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report
- Mid Stage Products (Phase II)
  - Comparative Analysis
- Delgocitinib: LEO Pharma
  - Product Description
  - Research and Development
  - Product Development Activities



Drug profiles in the detailed report

Early Stage Products (Phase I/II)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Preclinical and Discovery Stage Products

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Chronic hand eczema Key Companies

Chronic hand eczema Key Products

Chronic hand eczema- Unmet Needs

Chronic hand eczema- Market Drivers and Barriers

Chronic hand eczema- Future Perspectives and Conclusion

Chronic hand eczema Analyst Views

Chronic hand eczema Key Companies

Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Chronic hand eczema

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Chronic hand eczema
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Chronic hand eczema - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/CCFE8A0D4DFBEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CCFE8A0D4DFBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970